EFTA00804474.pdf

Report Status: Final (0) Quest Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR8391 ION Client #: 78300020 56W5265 EPSTEIN, JEFFREY Requisition: 0006872 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 65 BRUCE MOSKOWITZ, MD Gender: M Attn: NATIONWIDE ACCOUNT Collected: 11/23/2018 Phone: 561.366.0084 1411 N FLAGLER DR STE 7100 Received: 11/27/2018 109:51 EST Patient ID: 19530120MJE WEST PALM BEACH, FL 33401-3418 Reported: 11/28/2018 109:22 EST Health ID: 8573003290851249 Test Hams In Range Out Of Range Reference Range Lab PROTEIN, TOTAL AND PROTEIN ELECTROPHORESIS PROTEIN, TOTAL, SERUM MI PROTEIN, TOTAL 7.1 6.1-8.1 g/dL PROTEIN ELECTROPHORESIS TP ALBUMIN 4.2 3.8-4.8 g/dL ALPHA 1 GLOBULIN 0.3 0.2-0.3 g/dL ALPHA 2 GLOBULIN 0.7 0.5-0.9 g/dL BETA 1 GLOBULIN 0.6 0.4-0.6 g/dL BETA 2 GLOBULIN 0.4 0.2-0.5 g/dL GAMMA GLOBULIN 1.0 0.8-1.7 g/dL INTERPRETATION Normal Electrophoretic Pattern The above test was performed; however, the specimen was lipemic. LIPID PANEL, STANDARD CHOLESTEROL, TOTAL 216 H <200 mg/dL MI HDL CHOLESTEROL 23 L >40 mg/dL MI TRIGLYCERIDES 935 H <150 mg/dL MI LDL-CHOLESTEROL mg/dL (talc) MI LDL cholesterol not calculated. Triglyceride levels greater than 400 mg/dL invalidate calculated LDL results. Reference range: <100 Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors. LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 9.4 H <5.0 (talc) MI NON HDL CHOLESTEROL 193 H <130 mg/dL (talc) MI For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.1 mg/L TP The above test was performed; however, the specimen was lipemic. Average relative cardiovascular risk according to AHA/CDC guidelines. CLIENT SERVICES:866.697.8378 SPECIMEN: MR8391 ION PAGEI0F6 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00804474  Report Status: Final Quest —• Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR8391 ION Client #: 78300020 EPSTEIN, JEFFREY Collected: 11/23/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 65 Received: 11/27/2018 / 09:51 EST Gender: M Reported: 11/28/2018 / 09:22 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range Reference Range Lab For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk. 1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk. Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation. >10.0 Persistent elevation, upon retesting, may be associated with infection and inflammation. HONOCYSTEINE 12.7 H <11.4 umol/L MI Homocysteine is increased by functional deficiency of folate or vitamin B12. Testing for methylmalonic acid differentiates between these deficiencies. Other causes of increased homocysteine include renal failure, folate antagonists such as methotrexate and phenytoin, and exposure to nitrous oxide. COMPREHENSIVE METABOLIC MI PANEL GLUCOSE 111 H 65-99 mg/dL Fasting reference interval For someone without known diabetes, a glucose value between 100 and 125 mg/dL is consistent with prediabetes and should be confirmed with a follow-up test. UREA NITROGEN (BUN) 20 7-25 mg/dL CREATININE 0.95 0.70-1.25 mg/dL For patients >49 years of age, the reference limit for Creatinine is approximately 13% higher for people identified as African-American. eGFR NON-AFR. AMERICAN 84 > OR 60 mL/min/1.73m2 eGFR AFRICAN AMERICAN 97 > OR 60 mL/min/1.73m2 BUN/CREATININE RATIO NOT APPLICABLE 6-22 (calc) SODIUM 138 135-146 mmol/L POTASSIUM 4.4 3.5-5.3 mmol/L CHLORIDE 105 98-110 mmol/L CARBON DIOXIDE 24 20-32 mmol/L CALCIUM 9.9 8.6-10.3 mg/dL PROTEIN, TOTAL 7.1 6.1-8.1 g/dL ALBUMIN 4.4 3.6-5.1 g/dL GLOBULIN 2.7 1.9-3.7 g/dL (calc) ALBUMIN/GLOBULIN RATIO 1.6 1.0-2.5 (calc) BILIRUBIN, TOTAL 0.7 0.2-1.2 mg/dL ALKALINE PHOSPHATASE 60 40-115 U/L AST 23 10-35 U/L ALT 36 9-46 U/L HEMOGLOBIN Ale 5.7 H <5.7 % of total Hgb MI CLIENTSERIIICES:866.6971378 SPECIMEN: MR839110N PAGE 2 OF 6 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00804475  Report Status: Final raj Quest Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR8391 ION Client #: 78300020 EPSTEIN, JEFFREY Collected: 11/23/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 65 Received: 11/27/2018 109:51 EST Gender: M Reported: 11/28/2018 / 09:22 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range Reference Range Lab For someone without known diabetes, a hemoglobin Alc value between 5.7% and 6.4% is consistent with prediabetes and should be confirmed with a follow-up test. For someone with known diabetes, a value <7% indicates that their diabetes is well controlled. Alc targets should be individualized based on duration of diabetes, age, comorbid conditions, and other considerations. This assay result is consistent with an increased risk of diabetes. Currently, no consensus exists regarding use of hemoglobin Alc for diagnosis of diabetes for children. CALCIUM, IONIZED 5.2 4.8-5.6 mg/dL TP URIC ACID 6.9 4.0-8.0 mg/dL MI Therapeutic target for gout patients: <6.0 mg/dL IMMUNOFIXATION, SERUM TP INTERPRETATION NO MONOCLONAL PROTEIN DETECTED TSH 2.44 0.40-4.50 mIU/L MI T4 (THYROXINE), TOTAL 7.6 4.9-10.5 mcg/dL MI FREE T4 INDEX (T7) 2.3 1.4-3.8 T3 UPTAKE 30 22-35 % MI SED RATE BY MODIFIED MI WESTERGREN 11 < OR = 20 mm/h CBC (INCLUDES DIFF/PLT) MI WHITE BLOOD CELL COUNT 6.0 3.8-10.8 Thousand/uL RED BLOOD CELL COUNT 5.28 4.20-5.80 Million/uL HEMOGLOBIN 15.4 13.2-17.1 g/dL HEMATOCRIT 44.3 38.5-50.0 % MCV 83.9 80.0-100.0 fL MCH 29.2 27.0-33.0 pg MCHC 34.8 32.0-36.0 g/dL RDW 13.0 11.0-15.0 % PLATELET COUNT 273 140-400 Thousand/uL MPV 10.6 7.5-12.5 fL ABSOLUTE NEUTROPHILS 2892 1500-7800 cells/uL ABSOLUTE LYMPHOCYTES 2298 850-3900 cells/uL ABSOLUTE MONOCYTES 492 200-950 cells/uL ABSOLUTE EOSINOPHILS 270 15-500 cells/uL ABSOLUTE BASOPHILS 48 0-200 cells/uL NEUTROPHILS 48.2 LYMPHOCYTES 38.3 MONOCYTES 8.2 EOSINOPHILS 4.5 BASOPHILS 0.8 URINALYSIS, COMPLETE MI Sim Endhoto I IRON AND TOTAL IRON MI BINDING CAPACITY CLIENT SERVICES: 866.697.8378 SPECIMEN: MR839110N PAGE30F6 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00804476  Report Status: Final Quest Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR8391 ION Client #: 78300020 EPSTEIN, JEFFREY Collected: 11/23/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 65 Received: 11/27/2018 / 09:51 EST Gender: M Reported: 11/28/2018 / 09:22 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range Reference Range Lab IRON, TOTAL 91 50-180 mcg/dL IRON BINDING CAPACITY 336 250-425 mcg/dL (calc) % SATURATION 27 15-60 % (calc) FERRITIN 57 20-380 ng/mL MI VITAMIN B12 325 200-1100 pg/mL MI Please Note: Although the reference range for vitamin B12 is 200-1100 pg/mL, it has been reported that between 5 and 10% of patients with values between 200 and 400 pg/mL may experience neuropsychiatric and hematologic abnormalities due to occult B12 deficiency; less than 1₹ of patients with values above 400 pg/mL will have symptoms. C-REACTIVE PROTEIN 1.3 <8.0 mg/L MI MERCURY, BLOOD <5 <OR=10 mcg/L AT This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. PSA, TOTAL 0.6 < OR = 4.0 ng/mL MI The total PSA value from this assay system is standardized against the WHO standard. The test result will be approximately 20% lower when compared to the equimolar-standardized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind. This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease. TESTOSTERONE, FREE AMD (DIALYSIS) AND TOTAL,MS TESTOSTERONE, TOTAL, MS 153 L 250-1100 ng/dL Men with clinically significant hypogonadal symptoms and testosterone values repeatedly in the range of the 200-300 ng/dL or less, may benefit from testosterone treatment after adequate risk and benefits counseling. For additional information, please refer to http://education.questdiagnostics.com/faq/ TotalTestosteroneLCMSMSFAQ165 (This link is being provided for informational/ educational purposes only.) This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug CLIENTSERIIICES:866.697.8378 SPECIMEN: MR839110N PAGE 4 OF6 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00804477  Report Status: Final Quest —00 Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR839110N Client #: 78300020 EPSTEIN, JEFFREY Collected: 11/23/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 65 Received: 11/27/2018 I 09:51 EST Gender: M Reported: 11/28/2018 / 09:22 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range Reference Range Lab Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. TESTOSTERONE, FREE 42.5 35.0-155.0 pg/mL This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Endnote I * Test not performed. * * No specimen received. * CLIENT SERVICES: 866.697.8378 SPECIMEN: MR8391 ION PAGE5OF6 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00804478  Report Status: Final raj Quest Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR8391 ION Client #: 78300020 EPSTEIN, JEFFREY Collected: 11/23/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 65 Received: 11/27/2018 / 09:51 EST Gender: M Reported: 11/28/2018 / 09:22 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Endocrinology Test Name Result Reference Range Lab VITAMIN D,25-OH,TOTAL,IA 24 L 30-100 ng/mL MI Vitamin D Status 25-OH Vitamin D: Deficiency: <20 ng/mL Insufficiency: 20 - 29 ng/mL Optimal: > or = 30 ng/mL For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs). For more information on this test, go to: httpJ/education.questdiagnostics.com/faq/FAO163 (This link is being provided for informational/ educational purposes only.) Physician Comments: PERFORMING SITE: AMD QUEST DIAGNOSTICS/NIOIOLS CHANTILLY. 1422.5 NEWBROOK DRJVE CHANTILL Y. VA 201SI -2225 Laboratory Ducar PATRICK W. MASONAID.PHD.CLIA: 1900221801 AT QUEST DIAGNOSTICS...JUNTA. 1777 MONTREAL CIRCLE. IIICICER GA 30014.6802 Laboratory Director. ANDREW N YOUNG.AID.PHD.CLIA: 1100255931 MI QUEST DIAGNOSTICS.NIIAMI HMO COMMERCE PARKWAY. MIRAMAR. FL 330254938 Laboratory DUCCIOI: JULIE I. FRIEDMAN.MD.CLIA: If/002773M TP QUEST DIAGNOSTICSTAMPA.1223 E FOWLER AVE TAMPA. It 33617.2026 Laboratory Ihrector GLEN L IIORTIN.MD.PHD. CUA: 1000291120 CLIENT SERVICES: 866.697.8378 SPECIMEN: MR839110N PAGE 6 OF 6 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00804479